Can Ajovy (Fremanezumab) Cause Hair Loss?

What Is Fremanezumab and How Does It Work?

Fremanezumab, marketed as Ajovy, represents a breakthrough in migraine prevention as a CGRP (calcitonin gene-related peptide) receptor antagonist. This injectable medication works by blocking CGRP, a protein that plays a crucial role in migraine development and pain transmission. When CGRP levels rise, blood vessels in the brain dilate and become inflamed, contributing to the characteristic throbbing pain of migraines.

Ajovy is administered as either a monthly 225mg injection or a quarterly 675mg dose, providing flexibility for patients and healthcare providers. The medication received FDA approval in 2018 for both episodic and chronic migraine prevention in adults, marking a significant advancement in migraine management. Unlike traditional preventive medications that were originally developed for other conditions, fremanezumab was specifically designed to target the migraine pathway.

The medication's effectiveness stems from its ability to bind to CGRP receptors, preventing the protein from triggering the cascade of events that lead to migraine attacks. Clinical studies demonstrate that patients typically experience a 50% or greater reduction in monthly migraine days, significantly improving quality of life for those suffering from frequent episodes.

Clinical Trial Evidence and Hair Loss Incidence

Clinical trial data provides the most reliable information about fremanezumab's potential to cause hair loss. In Phase 2 and Phase 3 studies involving over 1,800 patients, alopecia (hair loss) was reported in approximately 1-2% of participants receiving fremanezumab compared to less than 1% in placebo groups. While this difference appears small, it represents a statistically significant increase that warranted inclusion in the medication's prescribing information.

The following table compares hair loss incidence across different CGRP inhibitors:

Most cases of hair loss in clinical trials were described as mild to moderate, with patients reporting diffuse thinning rather than patchy baldness. The onset typically occurred 2-4 months after treatment initiation, suggesting a relationship with hair growth cycles rather than immediate toxicity. Importantly, follow-up studies indicated that hair regrowth generally occurred within 3-6 months after medication discontinuation.

Understanding CGRP's Role in Hair Biology

The connection between CGRP and hair growth involves complex biological pathways that researchers are still investigating. CGRP receptors are present in hair follicles and surrounding tissues, where they may influence blood flow, inflammation, and cellular metabolism. Some studies suggest that CGRP normally promotes hair follicle health by supporting adequate blood supply and nutrient delivery to growing hair.

When CGRP activity is blocked by medications like fremanezumab, this disruption may affect the normal hair growth cycle. Hair follicles progress through three phases: anagen (growth), catagen (transition), and telogen (resting). CGRP inhibition might push more follicles into the telogen phase prematurely, leading to increased shedding and apparent thinning. Understanding the stress and hair connection helps explain how disrupting normal biological processes can impact hair health.

Research also indicates that CGRP may influence stem cell activity within hair follicles, potentially affecting the follicle's ability to regenerate and produce new hair. This mechanism could explain why some patients experience more pronounced hair loss than others, as individual variations in CGRP receptor density and sensitivity may determine susceptibility.

Real-World Experience and Patient Reports

Post-marketing surveillance through the FDA's Adverse Event Reporting System (FAERS) has provided additional insights into fremanezumab-related hair loss. Healthcare providers have reported cases ranging from mild thinning to more noticeable hair loss, with some patients discontinuing treatment due to cosmetic concerns. Online patient forums and support groups frequently discuss hair-related side effects, with experiences varying significantly among individuals.

Many patients describe a gradual onset of hair thinning that becomes noticeable during routine hair care activities like brushing or washing. Some report changes in hair texture or reduced growth rate before obvious thinning occurs. The pattern typically involves diffuse thinning across the scalp rather than localized patches, distinguishing it from other forms of alopecia. Similar to other medications that can affect hair health, the impact varies considerably between individuals.

Healthcare providers emphasize the importance of comprehensive evaluation when patients report hair changes, as multiple factors can contribute to hair loss. Stress from chronic migraines, nutritional deficiencies, hormonal changes, and other medications may all play roles. Drug-induced hair thinning requires careful assessment to determine the most likely cause and appropriate management strategy.

Management Strategies and Alternative Options

Patients experiencing hair loss while taking fremanezumab should discuss their concerns with healthcare providers rather than abruptly discontinuing treatment. Sudden cessation of migraine prevention can lead to rebound headaches and return of frequent migraines, potentially causing more distress than the hair loss itself. A gradual approach allows for proper evaluation and planning of alternative strategies.

Providers may recommend several approaches, including monitoring hair loss progression, implementing supportive hair care measures, or considering alternative migraine prevention options. Nutritional support, gentle hair care practices, and stress management techniques may help minimize further hair loss and support regrowth. Some patients benefit from consultation with dermatologists who specialize in hair disorders. Understanding how other medications might affect hair health helps inform treatment decisions.

For patients who cannot tolerate fremanezumab due to significant hair loss, alternative CGRP inhibitors or traditional preventive medications may be considered. While other CGRP blockers carry similar risks, individual responses vary, and some patients may tolerate different formulations better. Traditional options like topiramate, propranolol, or amitriptyline offer different risk profiles, though they come with their own potential side effects. The decision requires careful weighing of migraine control benefits against cosmetic concerns and quality of life impacts.

The Bottom Line

While hair loss is a documented but uncommon side effect of Ajovy (fremanezumab), affecting approximately 1-2% of patients, the decision to continue treatment should balance migraine control benefits against cosmetic concerns. Most hair loss appears reversible after discontinuation, and healthcare providers can help patients explore alternative prevention strategies if needed. Doctronic's AI doctor provides 24/7 access to medication guidance and can help evaluate side effects, having completed over 22 million consultations with 99.2% treatment plan alignment with board-certified physicians. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.